Dyslipidaemia: integration between primary and secondary care

摘要

It is the implementation of guidelines, not the guidelines themselves, that change clinical practice. This session examined some of the issues that were faced when interpreting national guidelines for local implementation. Local guidelines for the use of lipid lowering drugs have been in place and regularly updated for more than 10 years and were recently reviewed to incorporate the recommendations in the National Institute for Health and Clinical Excellence (NICE) lipid modification guideline1 and the relevant section of the NICE type 2 diabetes guideline.2 The process formed the basis of this talk.Lipid lowering drugs impact on practice in primary care and in a range of specialty areas. Membership of the local guideline development group reflected this with colleagues from primary care and a wide range of specialties, including those perhaps less likely to be represented, such as from mental health services and rheumatology.